Most patients of HoFH need additional agents, namely, microsomal triglyceride transport protein inhibitors, such as Lomitapide, indicated only for HoFH; and injectable second-generation antisense oligonucleotides, such as mipomersen; or ANGPTL-3 antibodies such as evinacumab. Here, ANGPTL3 is linked to homozygous familial hypercholesterolemia.